Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
28
01
2020
revised:
07
04
2020
accepted:
24
04
2020
pubmed:
3
5
2020
medline:
30
9
2021
entrez:
3
5
2020
Statut:
ppublish
Résumé
Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.
Identifiants
pubmed: 32359162
pii: 5828225
doi: 10.1093/jnci/djaa064
pmc: PMC7936057
doi:
Types de publication
Congress
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
234-243Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Am J Cancer Res. 2019 Jan 01;9(1):53-63
pubmed: 30755811
Cancer Res. 2016 Jan 1;76(1):73-82
pubmed: 26573799
J Tissue Eng Regen Med. 2019 May;13(5):812-822
pubmed: 30793851
Cell. 2016 Aug 11;166(4):950-962
pubmed: 27518565
Protein Cell. 2019 Nov;10(11):840-845
pubmed: 31236852
Lancet Oncol. 2016 Mar;17(3):378-388
pubmed: 26794930
Hum Pathol. 2012 Sep;43(9):1394-9
pubmed: 22401771
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Gene. 2018 Jan 15;640:28-42
pubmed: 28970150
Methods Mol Biol. 2017;1530:355-367
pubmed: 28150214
Cold Spring Harb Perspect Med. 2017 May 1;7(5):
pubmed: 28159833
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Tissue Antigens. 2003 May;61(5):403-7
pubmed: 12753660
Nat Commun. 2016 Jun 29;7:12037
pubmed: 27353360
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Mol Cancer Res. 2019 Aug;17(8):1613-1626
pubmed: 31043488
Eur Urol. 2016 May;69(5):866-74
pubmed: 26626617
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Clin Cancer Res. 2018 May 1;24(9):2044-2049
pubmed: 29440190
JAMA Oncol. 2017 Jul 1;3(7):913-920
pubmed: 27787547
Biochem Soc Trans. 2016 Jun 15;44(3):951-9
pubmed: 27284065
Nat Med. 2020 May;26(5):792-802
pubmed: 32405060
Oncogene. 2011 Nov 24;30(47):4697-706
pubmed: 21602888
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Cell Chem Biol. 2016 Dec 22;23(12):1490-1503
pubmed: 27866910
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
Clin Cancer Res. 2019 Apr 1;25(7):2174-2184
pubmed: 30670497
Cancer Lett. 2019 Aug 28;458:102-112
pubmed: 31100411
J Clin Invest. 2008 Mar;118(3):1099-109
pubmed: 18292810
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Nat Biotechnol. 2018 Jun;36(5):421-427
pubmed: 29608177
J Vis Exp. 2017 Apr 12;(122):
pubmed: 28448047
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Nano Lett. 2017 Mar 8;17(3):1326-1335
pubmed: 28273716
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Clin Cancer Res. 2018 Dec 1;24(23):5977-5989
pubmed: 30061365
Clin Genitourin Cancer. 2019 Feb;17(1):e195-e202
pubmed: 30459061
Trends Immunol. 2017 May;38(5):323-335
pubmed: 28262471
JAMA Oncol. 2019 Sep 5;:
pubmed: 31486842
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
EBioMedicine. 2016 Nov;13:90-98
pubmed: 27727003
Genome Med. 2016 Jul 27;8(1):80
pubmed: 27460926
Cancer Res. 2018 Jun 15;78(12):3135-3146
pubmed: 29724720
J Oncol Pract. 2017 Jul;13(7):414-421
pubmed: 28697319
Hum Mol Genet. 2017 Aug 1;26(15):2912-2922
pubmed: 28475717
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Clin Cancer Res. 2017 Feb 1;23(3):825-832
pubmed: 27553831
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282
pubmed: 29891694
Elife. 2016 Feb 22;5:
pubmed: 26901439
Cancer Immunol Res. 2017 Mar;5(3):182-190
pubmed: 28108630
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
Acta Biomater. 2019 Apr 1;88:211-223
pubmed: 30822553
Cancer Res. 2017 Jun 1;77(11):2893-2902
pubmed: 28572504
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344